Understand the valuation multiples, deal structures, and value drivers that determine what buyers will pay for an aesthetic surgery practice in today's lower middle market M&A landscape.
Find Cosmetic Surgery Center Businesses For SaleCosmetic surgery centers are typically valued on a multiple of Seller's Discretionary Earnings (SDE) for owner-operated practices under $1M in EBITDA, or on an EBITDA multiple for larger, more institutionalized centers with associate physicians and documented systems. Buyers apply a premium for practices with diversified procedure revenue across both surgical and high-volume non-surgical treatments, reduced key-man dependency, and clean regulatory and malpractice history. Valuation multiples in this sector range from 3.5x to 6x EBITDA, with the spread heavily influenced by physician dependency, staff retention risk, and compliance with state corporate practice of medicine laws.
3.5×
Low EBITDA Multiple
4.75×
Mid EBITDA Multiple
6×
High EBITDA Multiple
Lower multiples (3.5x–4x EBITDA) apply to practices where the selling surgeon personally drives 70%+ of revenue, has unresolved malpractice exposure, or lacks associate providers who can sustain operations post-sale. Mid-range multiples (4.5x–5x) reflect practices with a balanced surgical and non-surgical revenue mix, at least one associate physician or skilled NP, and clean financials. Premium multiples (5.5x–6x) are reserved for accredited centers with $2M+ EBITDA, documented patient acquisition systems, minimal key-man risk, and strong recurring non-surgical revenue — the profile most attractive to PE-backed aesthetic platform acquirers.
$3,200,000
Revenue
$780,000
EBITDA
5.0x
Multiple
$3,900,000
Price
Asset purchase using an MSO structure to separate the management services organization from the physician-owned professional corporation, in compliance with state CPOM regulations. Funded with an SBA 7(a) loan covering $3,120,000 (80%), a seller note of $390,000 (10%) contingent on a 24-month physician transition and patient retention rate above 85%, and $390,000 in buyer equity (10%). The selling surgeon agreed to a 2-year part-time clinical transition agreement compensated at fair market value, with a 5-year non-compete covering a 25-mile radius.
EBITDA Multiple
The most common institutional valuation method for cosmetic surgery centers generating $500K or more in annual EBITDA. The buyer calculates normalized EBITDA — adjusting for owner compensation, personal expenses, and one-time items — then applies a multiple based on practice quality, physician dependency, and growth trajectory. For a center with $1M in normalized EBITDA and strong associate coverage, a 5x multiple yields a $5M enterprise value.
Best for: PE-backed buyers, strategic acquirers, and multi-location aesthetic platform companies evaluating add-on acquisitions with $2M+ in revenue
Seller's Discretionary Earnings (SDE) Multiple
Used for smaller, owner-operated cosmetic surgery practices where the selling physician is the primary producer. SDE adds back the owner's total compensation, personal benefits, and non-recurring expenses to net income, reflecting the total economic benefit to a single owner-operator. SDE multiples in this sector typically range from 2.5x to 4x depending on practice size, transferability of patient relationships, and procedure mix.
Best for: Solo-physician practices with $1M–$2.5M in revenue being acquired by individual buyers, entrepreneurial physicians, or SBA-financed operators
Revenue Multiple
Occasionally used as a sanity-check or secondary valuation metric, particularly when a practice has suppressed earnings due to heavy reinvestment in equipment or staff buildout. Cosmetic surgery centers typically trade at 0.75x–1.5x trailing twelve-month revenue, with higher multiples reserved for practices with strong non-surgical recurring revenue and low overhead structures. This method is rarely used as the primary valuation basis by sophisticated buyers.
Best for: Early-stage valuation benchmarking, distressed practice scenarios, or when EBITDA is not yet stabilized due to recent expansion or equipment investment
Discounted Cash Flow (DCF)
A forward-looking valuation approach that projects future procedure volumes, revenue per patient, and margin trajectory, then discounts those cash flows to present value using a risk-adjusted rate. DCF analysis is most relevant for cosmetic surgery centers with demonstrable growth in non-surgical volume, a pipeline of new service lines (e.g., body contouring, hormone therapy), or a recently onboarded associate physician whose contribution has not yet been fully reflected in historical earnings.
Best for: PE buyers modeling 5-year hold periods, acquirers evaluating platform plays with multiple growth levers, or sellers whose trailing financials understate current earnings power
Associate Physicians and Mid-Level Provider Coverage
Nothing increases the valuation of a cosmetic surgery center more than documented evidence that revenue is not solely dependent on the selling surgeon. Practices with one or more associate physicians, physician assistants, or nurse practitioners who independently generate patient volume and perform non-surgical treatments command meaningfully higher multiples. Buyers evaluate whether these providers are under long-term employment agreements and whether patients follow them or the practice brand.
High-Volume Recurring Non-Surgical Revenue
Botox, dermal fillers, laser treatments, and medical-grade skincare create a predictable, high-margin recurring revenue stream that buyers treat as annuity-like income. A practice generating 30–40% of revenue from non-surgical repeat treatments has a more defensible revenue base than one relying exclusively on episodic surgical cases. Buyers will review patient retention rates, average visit frequency, and revenue per patient cohort to assess the durability of this income.
Accredited In-Office Surgical Suite
AAAHC or Joint Commission accreditation of an in-office operating room is a significant competitive moat and value driver. Accredited surgical suites allow the practice to perform cases outside of hospital settings — reducing costs, increasing scheduling flexibility, and improving patient experience. Buyers recognize the capital investment and regulatory complexity required to achieve and maintain accreditation, treating it as a barrier to entry that protects the practice's surgical case volume.
Diversified Procedure Mix Without Single-Case Concentration
Practices that generate revenue across multiple surgical categories — breast, body, face, and rhinoplasty — alongside non-surgical services are less exposed to trend shifts or competitive pressure in any single procedure category. Buyers will analyze revenue concentration by procedure type and flag practices where more than 40–50% of surgical revenue comes from a single procedure, particularly if that procedure faces commoditization or reimbursement pressure.
Clean Malpractice and Regulatory History
A cosmetic surgery center with zero unresolved malpractice claims, no board complaints, and current facility accreditation commands a material valuation premium. Buyers and their attorneys conduct exhaustive diligence on litigation history, and a single unresolved claim can trigger escrow holdbacks, purchase price reductions, or deal termination. Tail insurance coverage that is current and transferable is a non-negotiable expectation for any institutional acquirer.
Documented Patient Acquisition and Marketing Infrastructure
Practices with a systematic approach to new patient acquisition — including SEO-optimized digital presence, active social media with before/after content, patient referral programs, and CRM-tracked lead conversion — demonstrate that growth is the result of repeatable systems rather than the selling surgeon's personal network. Buyers place a premium on practices where new patient volume can be maintained and grown after the founding physician steps back.
Extreme Key-Man Dependency on the Selling Surgeon
When 80% or more of practice revenue is traceable to the personal reputation, surgical skill, or patient relationships of the selling physician, buyers will either heavily discount the valuation, structure an extended earnout tied to post-close revenue retention, or walk away entirely. This is the single most common reason cosmetic surgery center deals collapse or reprice. Sellers should ideally spend 12–24 months before going to market reducing this concentration by onboarding associate providers and transferring patient relationships to the practice brand.
Unresolved Malpractice Claims or Licensing Issues
Any open malpractice litigation, board of medicine complaints, Medicare or Medicaid exclusions, or DEA registration issues will create serious obstacles to closing. Buyers will insist on representations and warranties covering these areas, and unresolved matters will typically result in escrow holdbacks or purchase price reductions that can significantly erode net proceeds. Sellers should resolve or disclose all such matters prior to engaging with buyers.
Revenue Not Reflected in Clean Financial Statements
Cash payments, informal fee arrangements, barter services, or personal expenses run through the practice that are not properly documented in CPA-reviewed financials create immediate credibility problems with buyers and their lenders. SBA lenders require at minimum two to three years of clean tax returns and financial statements. Any discrepancy between reported revenue and actual collections will trigger renegotiation or deal abandonment, and may expose sellers to legal liability.
High Staff Turnover or Loss of Key Injectors and Aestheticians
Skilled nurse injectors, medical aestheticians, and laser technicians are often the face of the non-surgical side of the business and may have their own loyal patient followings. High turnover in these roles — or the departure of a top injector during the sale process — directly threatens the recurring revenue stream that buyers are paying for. Employment agreements with non-solicitation clauses and retention bonuses tied to deal closing are standard tools to mitigate this risk.
Outdated Equipment and Deferred Capital Expenditures
Cosmetic surgery centers that have not reinvested in laser platforms, body contouring devices, or surgical suite equipment face buyer pushback during diligence when capital expenditure requirements become apparent. Buyers will model the cost to refresh or replace aging equipment and subtract that figure from their valuation, or use it as leverage to renegotiate purchase price. Sellers who proactively address deferred capex before going to market preserve more of their asking price.
CPOM Non-Compliance or Poorly Structured Corporate Entities
Many cosmetic surgery practices in the lower middle market were not structured with an eventual sale in mind, resulting in corporate entities that do not comply with state corporate practice of medicine laws. When the business entity and medical professional corporation are commingled or improperly documented, buyers face significant legal restructuring costs and regulatory risk. Practices without a clean MSO/PC separation will require legal remediation before any institutional buyer will proceed, adding time and cost to the transaction.
Find Cosmetic Surgery Center Businesses For Sale
Signal-scored targets with seller motivation, multiples, and outreach — free to join.
Most cosmetic surgery centers in the lower middle market sell for 3.5x to 6x normalized EBITDA. Where your practice falls within that range depends primarily on physician dependency, procedure mix diversification, staff stability, malpractice history, and the presence of documented patient acquisition systems. A solo-physician practice where the seller performs 90% of all procedures will likely trade at the lower end of the range, while an accredited center with associate providers and strong recurring non-surgical revenue can command 5x or above from strategic or PE-backed buyers.
Yes, but the transaction structure must comply with state corporate practice of medicine laws, which in most states prohibit non-physicians from owning or controlling a medical practice. The standard solution is a Management Services Organization structure, where the non-physician buyer owns the MSO — which controls the real estate, equipment, staff, and administrative operations — while a licensed physician owns and operates the professional corporation that employs physicians and bills for medical services. The MSO and PC are linked through a management services agreement. This structure is well-established in aesthetic medicine and is regularly financed with SBA loans.
Physician key-man risk is the most significant valuation discount factor in cosmetic surgery M&A. If a buyer's quality of earnings analysis shows that the departing surgeon personally drives the majority of patient volume and revenue, they will either apply a lower multiple, structure a significant portion of the purchase price as an earnout tied to post-close revenue retention, or require an extended transition period. Sellers who proactively reduce key-man risk by onboarding associate physicians or nurse practitioners before going to market consistently achieve higher multiples and cleaner deal structures.
Yes, cosmetic surgery center acquisitions are generally SBA 7(a) eligible, and SBA financing is commonly used for deals in the $1M–$5M range. The SBA lender will require clean CPA-reviewed financial statements for 2–3 years, evidence that the practice can service debt without the selling physician as the sole revenue driver, and a viable transition plan. Deals where the seller is also the sole physician often require the buyer to either be a licensed physician or have a credible clinical staffing solution in place. Working with an SBA lender experienced in medical practice acquisitions significantly improves the likelihood of approval.
Malpractice history is scrutinized intensively during due diligence. Open or unresolved claims will typically result in purchase price reductions, escrow holdbacks equal to the estimated claim exposure, or representations and warranties insurance requirements. Even resolved claims are reviewed for patterns that suggest systemic quality or consent issues. Sellers should ensure that adequate tail coverage is in place for all prior acts, that all resolved claims are documented with releases, and that their malpractice carrier has confirmed coverage transferability or run-off terms before engaging with buyers.
In an asset purchase, the buyer acquires specific assets of the practice — equipment, patient records, trade names, and goodwill — without assuming the seller's corporate liabilities, including unknown malpractice exposure from prior cases. This is the most common structure for cosmetic surgery center acquisitions and is required in most states to comply with CPOM laws using an MSO/PC framework. In a stock purchase, the buyer acquires the seller's corporate entity directly, inheriting all historical liabilities. Stock purchases occasionally occur when the seller has favorable lease terms, specific licenses, or vendor contracts that are not assignable in an asset deal, but they require significantly more robust representations and warranties protections for the buyer.
Most cosmetic surgery center sales in the lower middle market take 12 to 24 months from the decision to sell through closing. The timeline includes 3–6 months of exit preparation (financial clean-up, MSO/PC restructuring, associate provider recruitment), 3–6 months of marketing and buyer qualification, and 3–6 months of due diligence, financing, and legal documentation. Deals with complex CPOM compliance issues, unresolved malpractice matters, or SBA financing requirements tend toward the longer end of the timeline. Engaging a healthcare-specialized M&A advisor early in the process is the single most effective way to compress the timeline and maximize exit value.
More Cosmetic Surgery Center Guides
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers